Arcturus Therapeutics and CSL Report EMA’s Validation of MAA for ARCT-154 Vaccine to Prevent COVID-19
Shots: The EMA has validated the MAA for ARCT-154, a next-generation mRNA vaccine...
Novavax’s Nuvaxovid Receives EC’s Marketing Authorization for the Prevention of COVID-19
Shots: The EC has granted full marketing authorization for Nuvaxovid (NVX-CoV2373)...
Merck’s Lagevrio (molnupiravir) Missed Primary Endpoints in P-III Trial (MOVe-AHEAD) for Post-Exposure Prophylaxis to Prevent COVI...
Shots: The P-III trial (MOVe-AHEAD) evaluating Lagevrio (800mg) vs PBO in 1500 pat...
Novavax Initiates P-II Trial of COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
Shots: The company initiates the P-II trial, conducted in 2 parts evaluating the c...
Junshi Biosciences Reports P-III Clinical Trial Results of VV116 for Severe COVID-19
Shots: The P-III trial results published in
Jiangsu Recbio Technology Reports P-II Study Results of Two-Component COVID-19 Vaccine ReCOV
Shots: The P-II study evaluating the immunogenicity & safety profile of recomb...
